David Lubner

David Charles Lubner is an Independent Director at Crescent Biopharma, Inc. since 2025, Partner at RA Capital Management LP (Private Equity) since 2025, Independent Director at Braveheart Bio, Inc. starting 2026, Independent Director at Gemini Therapeutics Sub, Inc. since 2020, Director at Cerevance, Inc. since 2020, Independent Director at Dyne Therapeutics, Inc. since 2020, Non-Executive Director at Ichnos Glenmark Innovation, Inc., and Member of The American Institute of Certified Public Accountants.
Former roles include Director at NightstaRx Ltd., Independent Non-Executive Director at Nightstar Therapeutics Ltd. from 2017 to 2019, Independent Director at Therapeutics Acquisition Corp.
from 2020 to 2021, Independent Director at Vor Biopharma, Inc. from 2020 to 2025, Independent Director at Cargo Therapeutics, Inc. from 2023 to 2025, Independent Director at Gemini Therapeutics, Inc. from 2020 to 2022, Independent Director at POINT Biopharma Global, Inc. from 2021 to 2023, Independent Director at Arcellx, Inc. from 2020 to 2026, Chief Financial Officer at PharMetrics, Inc. from 1999 to 2005, Chief Financial Officer & Senior Vice President at Tetraphase Pharmaceuticals, Inc. from 2010 to 2016, Chief Financial Officer, Secretary & Executive VP at RA Pharmaceuticals, Inc. from 2016 to 2020, and Chief Financial Officer & Vice President at ProScript, Inc. from 1996 to 1999.
Education includes a graduate degree from Bentley University conferred in 1993 and an undergraduate degree from Northeastern University conferred in 1987.